FindTrial
Sign In

The Tumor Mutation Burden in Gastro-entero-pancreatic-neuroendocrine Tumors

The Tumor Mutation Burden in Gastro-entero-pancreatic-neuroendocrine Tumors

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0007980
Enrollment
100
Registered
2022-12-08
Start date
2022-10-25
Completion date
Unknown
Last updated
2023-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Samsung Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients diagnosed with gastro-entero-pancreatic-neuroendocrine tumors

Exclusion criteria

Exclusion criteria: Patients did not evaluated NGS

Design outcomes

Primary

MeasureTime frame
Tumor mutation burden—

Secondary

MeasureTime frame
PD-L1 expression—

Countries

Korea, Republic of

Contacts

Public ContactSun Young Jeong

Samsung Medical Center

jsyoung0727@naver.com+82-2-3410-5862

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026